15,971 Shares in DexCom, Inc. $DXCM Bought by Centaurus Financial Inc.

Centaurus Financial Inc. bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 15,971 shares of the medical device company’s stock, valued at approximately $1,076,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Formula Growth Ltd. bought a new stake in DexCom during the second quarter valued at about $926,000. Public Employees Retirement System of Ohio acquired a new position in shares of DexCom during the 2nd quarter worth about $13,944,000. Corient Private Wealth LP bought a new stake in DexCom during the 2nd quarter valued at approximately $8,400,000. Parallax Volatility Advisers L.P. bought a new stake in DexCom during the 2nd quarter valued at approximately $231,000. Finally, Bamco Inc. NY acquired a new stake in DexCom in the 2nd quarter valued at approximately $16,501,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares in the company, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,035 shares of company stock valued at $5,446,673 in the last 90 days. Insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Bank of America cut their price target on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. Benchmark raised their price objective on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, Royal Bank Of Canada raised their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $88.71.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $89.29 on Friday. The firm has a market capitalization of $33.69 billion, a PE ratio of 35.29, a PEG ratio of 1.50 and a beta of 1.41. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59. The business’s 50 day moving average is $78.84 and its 200-day moving average is $71.47.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.48 earnings per share. Sell-side analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.